Marshall Wace LLP raised its stake in Humana Inc (NYSE:HUM) by 314.6% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 80,138 shares of the insurance provider’s stock after buying an additional 60,809 shares during the period. Marshall Wace LLP owned about 0.06% of Humana worth $27,128,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors also recently added to or reduced their stakes in the company. Matthew Goff Investment Advisor LLC purchased a new stake in Humana in the 3rd quarter valued at about $64,000. Stratos Wealth Partners LTD. purchased a new stake in Humana in the 3rd quarter valued at about $108,000. Honkamp Krueger Financial Services Inc. purchased a new stake in Humana in the 3rd quarter valued at about $108,000. Sun Life Financial INC boosted its position in Humana by 120.7% in the 2nd quarter. Sun Life Financial INC now owns 373 shares of the insurance provider’s stock valued at $111,000 after buying an additional 204 shares during the period. Finally, Migdal Insurance & Financial Holdings Ltd. boosted its position in Humana by 2,984.6% in the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 401 shares of the insurance provider’s stock valued at $119,000 after buying an additional 388 shares during the period. 92.90% of the stock is owned by institutional investors.
NYSE:HUM opened at $306.00 on Friday. Humana Inc has a one year low of $242.00 and a one year high of $355.88. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.68 and a quick ratio of 1.68. The stock has a market capitalization of $43.39 billion, a PE ratio of 26.13, a price-to-earnings-growth ratio of 1.50 and a beta of 0.99.
Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, November 7th. The insurance provider reported $4.58 EPS for the quarter, topping the consensus estimate of $4.29 by $0.29. The firm had revenue of $14.21 billion during the quarter, compared to analyst estimates of $13.97 billion. Humana had a net margin of 2.70% and a return on equity of 19.10%. During the same quarter in the previous year, the business posted $3.39 EPS. Research analysts forecast that Humana Inc will post 14.43 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 25th. Investors of record on Monday, December 31st will be paid a dividend of $0.50 per share. The ex-dividend date is Friday, December 28th. This represents a $2.00 annualized dividend and a dividend yield of 0.65%. Humana’s dividend payout ratio (DPR) is presently 11.96%.
HUM has been the subject of several research reports. MED boosted their price objective on shares of Humana from $350.00 to $373.00 and gave the company an “outperform” rating in a research report on Thursday, November 8th. Royal Bank of Canada boosted their price objective on shares of Humana from $318.00 to $349.00 and gave the company a “sector perform” rating in a research report on Thursday, November 8th. Zacks Investment Research lowered shares of Humana from a “buy” rating to a “hold” rating in a report on Friday, October 5th. Credit Suisse Group boosted their price target on shares of Humana from $370.00 to $390.00 and gave the company an “outperform” rating in a report on Thursday, November 8th. Finally, Bank of America boosted their price target on shares of Humana from $400.00 to $415.00 and gave the company a “buy” rating in a report on Thursday, November 8th. Seven analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $352.10.
In related news, insider Roy A. Beveridge sold 4,622 shares of the business’s stock in a transaction that occurred on Thursday, November 8th. The shares were sold at an average price of $341.06, for a total transaction of $1,576,379.32. Following the completion of the transaction, the insider now owns 10,621 shares in the company, valued at approximately $3,622,398.26. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Bruce D. Broussard sold 18,000 shares of the business’s stock in a transaction that occurred on Monday, September 10th. The stock was sold at an average price of $328.66, for a total transaction of $5,915,880.00. Following the transaction, the chief executive officer now owns 71,085 shares of the company’s stock, valued at approximately $23,362,796.10. The disclosure for this sale can be found here. Insiders own 0.60% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Marshall Wace LLP Grows Holdings in Humana Inc (HUM)” was first posted by American Banking News and is the property of of American Banking News. If you are reading this article on another website, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.americanbankingnews.com/2018/12/08/marshall-wace-llp-grows-holdings-in-humana-inc-hum.html.
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company operates through four segments: Retail; Group and Specialty; Healthcare Services; and Individual Commercial. The Retail segment offers Medicare and supplemental benefit plans to individuals or through group accounts.
Featured Article: Cost of Equity
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc (NYSE:HUM).
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.